Clinical trial · Interventional
Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer
Cisplatin Combined With Irinotecan or Etoposide for Untreated Extensive-stage Small Cell Lung Cancer: a Multicenter Randomized Control Clinical Trial
NCT02323737CI-TRIAL-00016480completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with untreated extensive-stage small cell lung cancer(SCLC) were randomly assigned to receive either irinotecan/cisplatin (IP) or etoposide/cisplatin(EP), The association of efficacy and toxicity of IP regimen was analyzed.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extensive-stage Small Cell Lung Cancer | Lung Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Etoposide and cisplatin | Drug | — | UNRESOLVED |
| Irinotecan and cisplatin | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Irinotecan and cisplatin
- description
- The IP regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1.
- interventionNames
- Drug: Irinotecan and cisplatin
- type
- ACTIVE_COMPARATOR
- label
- Etoposide and Cisplatin
- description
- The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1.
- interventionNames
- Drug: Etoposide and cisplatin
Primary outcomes (1)
- measure
- progression-free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) of 0 to 2 * A life expectancy of at least 3 months * Measurable lesions * Adequate hematologic function Exclusion Criteria: * Infection * Myocardial infarction within the preceding three months * Symptomatic brain metastases or receiving radiotherapy less than 4 weeks * Pregnancy or breast-feeding
References
Publications (0)
Data not yet available
No reference posted for this study.